Biogen (BIIB) is set to announce its Q2/15 earnings results before the market open on Friday, July 23rd. Analysts expect the biotech company to report earnings per share of $4.10 and revenue of $2.71 billion. That would be 28c higher the $3.82 per share posted last quarter and 61c higher the $3.49 posted in the second quarter of 2014. Revenue is projected to be 29% higher than the $2.1 billion posted in the same period a year earlier. Meanwhile, EarningsWhisper.com reports a whisper number of $4.18 per share.
As a quick reminder, Biogen reported 1Q/15 EPS of $3.82 vs. $3.92 consensus. Revs came in at $2.56 billion vs. the $2.66 billion consensus.
On valuation measures, Biogen Inc. shares have a T-12 price/sales ratio of 9.10 and a price/book for the same period of 7.90. EPS is $13.85. The name has a current market cap of $91.00 billion and a median Wall Street price target of $466 with a high target of $525. Currently, there are 11 analysts that rate BIIB a ‘Buy’, 9 rate it a ‘Hold’. No analyst rates it a ‘Sell’.
BIIB shares have declined 6.19% in the last 4 weeks and 7.51% in the past three months. Over the past 5 trading sessions the stock has lost 2.20%.
The Cambridge, Massachusetts-based company is up 29.00% year-over-year, compared with a 6.35% gain in the S&P 500.
Update: Biogen Inc. just reported second quarter EPS of $4.22, compared to the consensus estimate of $4.10. Revenues increased 7.0% from last year to $2.59 billion. Analysts expected revenues of $2.71 billion. GAAP net income attributable to co. for Q215 came in at $927 million, an increase of 30% versus the same period in the prior year.
For FY15, BIIB provided EPS guidance of $15.50 – $15.95 versus consensus of $16.75 per share. The company also issued revenue projection of $10.29 – $10.48 billion, compared to the consensus revenue estimate of $11.00 billion.
The stock is currently down $25, or 7%, to $359.00.